Articles

In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy.  We have often heard these terms used interchangeably but the distinction between the two is important in a clinical trial with imaging.  Imaging biomarkers are often root contributors to a clinical trial’s endpoints, but they are not the same.

The Value of Standardized Quality and Performance Metrics in Clinical Trials It’s not just tumor measurements that matter! Quality and Performance Measurements are critical too. Imaging biomarker metrics are not the only measurements that matter in oncology imaging trials. Quality and performance metrics are just as important and necessary for running a successful clinical trial […]

Different types of medical imaging response criteria: morphological measures In oncology clinical trials, therapy is generally assessed using imaging response criteria involving imaging biomarkers. Imaging response criteria are used to define a “treatment response” status, used by the radiologist to evaluate whether the response to therapy is complete or partial or conversely, if the disease […]

Medical images management: how implementing proper processes and quality control can ensure maximum operational effectiveness and regulatory compliance Between February 2018 and March 2019, ~44.9 million diagnostic imaging tests were performed in England[i]. That so many imaging tests were performed in a country with a population of ~66.8 million[ii] provides a small snapshot of the […]

Business Intelligence-based reporting optimizes the operational efficiency of clinical trial imaging services Business Intelligence (BI) is the combination of business analytics, data mining, data visualization, data tools and infrastructure, and best practices, which together can transform data into actionable insights that inform an organization’s business decisions . As an imaging CRO, Median uses Business Intelligence […]

Immunotherapy Update: Recent Advances in CAR T-cell Therapy As a measure of its promise, chimeric antigen receptor (CAR) T-cell therapy – where patients’ own immune cells are collected, genetically changed and used to treat their cancer – is the American Society of Clinical Oncology (ASCO) Advance of the Year for 2018.[i] This approach represents an […]